Search Results

• • 4 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.

  Authors:Christopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, Najib M Rahman, Gail Hayward, Duncan B Richards, et al.From:The Lancet (Vol. 401, Issue 10373) Peer-Reviewed

  Jan. 28, 20231,196 words Article

   Abstract Only

• Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.

  Authors:Melinda J Hamer, Katherine V Houser, Amelia R Hofstetter, Ana M Ortega-Villa, Christine Lee, Anne Preston, et al.From:The Lancet (Vol. 401, Issue 10373) Peer-Reviewed

  Jan. 28, 2023827 words Article

   Abstract Only

• Systemic sclerosis.

  Authors:Elizabeth R Volkmann, Kristofer Andréasson, and Vanessa SmithFrom:The Lancet (Vol. 401, Issue 10373) Peer-Reviewed

  Jan. 28, 2023251 words Brief article

   Abstract Only

• Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.

  Authors:Srdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T Kuykendall, et al.From:The Lancet (Vol. 401, Issue 10373) Peer-Reviewed

  Jan. 28, 20231,271 words Clinical report

   Abstract Only